AMPK:a nutrient and energy sensor that maintains energy homeostasis by Hardie, D. Grahame et al.
                                                              
University of Dundee
AMPK
Hardie, D. Grahame; Ross, Fiona A.; Hawley, Simon A.
Published in:
Nature Reviews Molecular Cell Biology
DOI:
10.1038/nrm3311
Publication date:
2012
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012). AMPK: a nutrient and energy sensor that maintains energy
homeostasis. Nature Reviews Molecular Cell Biology, 13(4), 251-262. DOI: 10.1038/nrm3311
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 14. Dec. 2017
1	  
AMPK - a nutrient and energy sensor that maintains energy homeostasis 
D. Grahame Hardie, Fiona A. Ross and Simon A. Hawley 
Division of Cell Signalling & Immunology, College of Life Sciences, University of Dundee, Dow 
Street, Dundee, DD1 5EH, Scotland, UK 
Nature Reviews Molecular Cell Biology 13, 251–262 (2012), https://www.nature.com/articles/
nrm3311   DOI:10.1038/nrm3311 
	   2	  
Preface 
AMP-activated protein kinase (AMPK) is a crucial cellular energy sensor. Once activated by falling 
energy status, it promotes ATP production by increasing the activity or expression of proteins involved 
in catabolism, while conserving ATP by switching off biosynthetic pathways. AMPK also regulates 
metabolic energy balance at the whole body level. For example, it mediates the effects of agents acting 
on the hypothalamus that promote feeding, and entrains circadian rhythms of metabolism and feeding 
behavior. Finally, recent studies reveal that AMPK conserves ATP levels through the regulation of 
processes other than metabolism, such regulation of the cell cycle and neuronal membrane excitability. 
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Introduction 
Just like a mobile electronic device, every living cell contains a “rechargeable battery” formed by pairs 
of interconvertible chemicals. The key chemicals within the cell are ATP and ADP, interconverted by 
the reaction ATP ↔ ADP + phosphate. This reaction is maintained by catabolism many orders of 
magnitude away from equilibrium, yielding a high ratio of ATP to ADP that is used to drive energy-
requiring processes. In animal cells ATP is mainly generated via the mitochondrial ATP synthase, thus 
“charging the battery”. Almost every other function that cells perform requires energy, and most are 
driven by the hydrolysis of ATP back to ADP and phosphate, thus “discharging the battery”. Clearly, 
ATP generation needs to remain in balance with ATP consumption, and regulatory proteins that sense 
ATP and ADP levels would be a logical way to achieve this. However, all eukaryotic cells express high 
levels of adenylate kinase, and the reversible reaction it catalyzes (2ADP ↔ ATP + AMP) is usually 
maintained close to equilibrium. This means that any rise in the ADP:ATP ratio, which signifies falling 
energy status, causes the adenylate kinase reaction to be displaced towards ATP and AMP production. 
Thus, falling cellular energy is associated with increases not only in ADP, but also AMP. The relative 
increase in concentration is always much greater for AMP than ADP, although its absolute 
concentration remains lower than that of ADP unless energy stress becomes quite severe (Fig. 1). Thus, 
it seems logical that proteins sensing cellular energy status should monitor either the ADP:ATP or 
AMP:ATP ratio, or both. A small number of metabolic enzymes do directly sense the AMP:ATP ratio, 
including the muscle isoforms of glycogen phosphorylase [G] and phosphofructokinase [G] (which are 
involved in glycogen breakdown and glycolysis, and are activated by an increasing AMP:ATP ratio), 
and fructose-1,6-bisphosphatase (which is involved in gluconeogenesis, and is inhibited by an 
increasing AMP:ATP ratio). However, the principal energy sensor in most eukaryotic cells appears to 
be the AMP-activated protein kinase (AMPK)1. In support of this, increases in AMP:ATP and 
ADP:ATP ratios during stresses such as muscle contraction2, ischemia in cardiac muscle3, or treatment 
of hepatocytes with metformin4 are larger in cells or tissues in which AMPK, or its essential activating 
upstream kinase liver kinase B1 (LKB1), have been knocked out.  In this Review article, we describe 
how AMPK monitors cellular energy status by sensing increases in the ratios of AMP:ATP and 
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ADP:ATP, as well as other signals. Moreover, we examine how it regulates energy balance at the 
cellular level, by activating catabolic pathways that generate ATP, while conserving ATP by down-
regulating anabolic pathways. Finally, we discuss results showing that AMPK also regulates 
metabolism and energy balance at the whole body level, especially via effects on the hypothalamus, as 
well as recent findings suggesting that AMPK conserves energy by regulating non-metabolic processes, 
such as the cell cycle and neuronal membrane excitability. 
AMPK – subunits and regulation 
Genes encoding AMPK subunits are found in essentially all eukaryotes. AMPK and its orthologs 
appear to exist universally as heterotrimeric complexes comprising a catalytic α subunit and regulatory 
β and γ subunits, the domain organization of which are summarized in Fig. 2. The kinase activity of the 
αβγ complexes, in animals from nematodes to humans, is instantaneously increased by AMP by as 
much as 10-fold, although due to technical limitations with the assay5 the effect observed is usually 
smaller. It has been argued that this allosteric activation [G] by AMP (which gave the kinase its name) 
may not be relevant under physiological conditions because of competition at the allosteric site by ADP 
and ATP6. However, as shown in Fig. 1, an increase in the ADP:ATP ratio of only 10-fold is sufficient 
for the cellular concentrations of the three adenine nucleotides to become equal. Although this would 
represent quite a severe stress and might only occur in pathological states (such as ischemia) rather than 
under more physiological conditions (such as exercise), the ATP:ADP ratio would still be still many 
orders of magnitude away from equilibrium and could still drive energy-requiring processes. 
 AMPK catalytic subunits contain a conventional serine/threonine kinase domain at the N-terminus. 
In all species, the activity of the complex increases more than 100-fold5 when a conserved threonine 
residue in the activation loop [G] (which is conventionally referred to as Thr172 due to its position in 
the original rat sequence7)is phosphorylated by upstream kinases. In mammals the major upstream 
kinases are the LKB1:STRAD:MO25 complex [G] 8-10 (originally identified genetically as a tumor 
suppressor) and the Ca2+/calmodulin-activated protein kinases kinases, especially CaMKKβ11-13. 
 The LKB1 complex provides a high basal level of phosphorylation at Thr-172 that is modulated by 
the binding of AMP to the AMPK-γ subunit, which promotes phosphorylation and inhibits 
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dephosphorylation14, 15. Although allosteric activation is only caused by AMP, it has recently been 
found that the effects on phosphorylation and dephosphorylation can also be produced by ADP16, 17. 
The effects of AMP and ADP on phosphorylation require N-terminal myristylation [G] of the β subunit 
17, 18. Since AMP and ADP bind the γ subunits of AMPK with similar affinity to ATP16 (which does not 
cause activation), and ADP is usually present in cells at higher concentrations than AMP (Fig. 1), ADP 
may be the key activating signal that promotes net Thr-172 phosphorylation during moderate energy 
stress. However, allosteric activation by AMP would further amplify activation during a more severe 
stress. This complex mechanism (Fig. 1) allows the system to provide a graded response of AMPK 
activity over a wide range of stress levels. 
 The alternative activating pathway, involving CaMKKβ, triggers activation of AMPK in response to 
increases in cell Ca2+ without necessarily requiring any change in AMP or ADP levels. In tumor cells 
that have lost the tumor suppressor LKB1 due to somatic mutations, treatments that increase AMP and 
ADP levels do not normally activate AMPK8, because basal CaMKKβ activity is too low for the effects 
of nucleotide binding on phosphorylation status to become evident. However, these treatments can 
cause AMPK activation in such cells if intracellular Ca2+ is also elevated19. This emphasizes that the 
effects of AMP and/or ADP on Thr172 phosphorylation status are a result of their binding to AMPK, 
and are independent of the upstream kinases and phosphatases that phosphorylate or dephosphorylate 
Thr172. 
AMPK - structure 
 Although there is not yet a structure for a complete AMPK heterotrimer, the structures of various 
combinations of domains have been determined by X-ray crystallography. At the N-terminus of the α 
subunit is a conventional kinase domain immediately followed by an auto-inhibitory domain (AID), so-
called because constructs containing the kinase domain plus the AID are much less active than those 
containing the kinase domain alone20, 21. The AID is followed by an extended “linker peptide” that 
connects the AID to the C-terminal domain (α-CTD). A recent structure16 showed that this linker 
(colored red in Figs. 2 and 3) wraps around the γ subunit as if holding it in a tight embrace. 
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 The β subunits contain a carbohydrate-binding module or CBM (absent in the constructs used to 
generate the structure in Fig. 3), which causes mammalian AMPK to associate with glycogen 
particles22, 23. The functional significance of this remains uncertain, although it may serve to co-localize 
AMPK with downstream targets located in the glycogen particle, such as glycogen synthase. The β 
subunit C-terminal domain (β-CTD) interacts with both the α-CTD and the γ subunit, thus forming the 
core of the complex. The γ subunits contain four tandem repeats, numbered CBS1 through CBS4 in 
Figs. 2 and 3, of a sequence motif termed a CBS repeat [G] 24. These occur in a small number of other 
proteins (including cystathionine β-synthase (CBS)), usually as just two repeats that assemble to form a 
Bateman domain [G]25, with ligand-binding sites in the cleft between the repeats26. Most Bateman 
domains bind adenosine-containing ligands, usually ATP but in one case S-adenosyl methionine27, and 
mutations in them are associated with several human diseases, including a heart disease caused by 
mutations affecting the AMPK-γ2 subunit26, 27. In AMPK the four CBS repeats in the γ subunits form a 
flattened disk with one repeat in each quadrant (seen from two different sides in Fig. 3), containing four 
potential ligand-binding sites in the centre. These sites are numbered 1-4 according to the number of 
the repeat carrying a conserved aspartate residue involved in ligand binding6, and have variable 
occupancies in the crystal structures of partial complexes from mammals and fungi16, 28-30. In the 
mammalian γ1 subunit, site 2 appears to be always empty, site 4 to have a tightly-bound AMP, whereas 
sites 1 and 3 represent the regulatory sites that bind AMP, ADP or ATP in competition. AMP binding 
to site 1 appears to cause allosteric activation, while binding of AMP or ADP to site 3 appears to 
modulate the phosphorylation state of Thr-17216. A model16 that can explain how binding of AMP or 
ADP, but not ATP, protects Thr-172 against dephosphorylation has been discussed previously31. 
 One long-standing puzzle has been the identity of the signals that activate AMPK orthologs in fungi 
and plants, which are not allosterically activated by AMP32, 33. Under conditions where the S. cerevisiae 
SNF1 complex is activated, such as during glucose starvation, there are very large increases in 
AMP:ATP and ADP:ATP ratios32. The γ subunits in fungi and plants contain four CBS repeats as in 
mammals, and crystal structures of partial complexes from S. pombe have been solved with AMP, ADP 
and/or ATP bound at different sites30, 34. These observations support the idea that the activating signal 
is an adenine nucleotide in fungi as in mammals, and it was recently reported that ADP inhibits 
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dephosphorylation and inactivation of the S. cerevisiae complex35, with AMP having a smaller effect36. 
AMP had already been shown to inhibit dephosphorylation of a plant SnRK1 complex37. These results 
suggest that ADP and/or AMP may be the elusive signals that activate the fungal and plant enzymes, 
but that they work only via effects on the phosphorylation state of the kinase, and not via the additional 
allosteric mechanism. 
Regulation of AMPK in intact cells 
In mammalian cells, AMPK is activated by many different types of metabolic stress, drugs and 
xenobiotics by the mechanisms described above, involving increases in cellular AMP, ADP or Ca2+. 
These can now be regarded as the classical or “canonical” AMPK activation mechanisms. However, 
recent work suggests that other stimuli activate AMPK via mechanisms that do not involve changes in 
the levels of AMP, ADP and Ca2+, which can therefore be termed “non-canonical” mechanisms. These 
distinct types of mechanism are addressed below. 
Activation by metabolic stresses, drugs and xenobiotics 
The canonical mechanisms of activation of mammalian AMPK, which involve increases in AMP and 
ADP (Fig. 1) explain why AMPK is activated by stresses that inhibit the catabolic production of ATP, 
such as starvation for glucose38 or oxygen39 or addition of a metabolic poison40, as well as by stresses 
that increase ATP consumption such as muscle contraction41. AMPK is also switched on by numerous 
drugs and xenobiotics, including anti-diabetic drugs (such as metformin, phenformin and 
thiazolidinediones42, 43), plant products reputed to have health-promoting properties (resveratrol from 
grapes and red wine44, epigallocatechin gallate from green tea, capsaicin from peppers45, curcumin 
from turmeric46, and even garlic47), and plant products used in traditional Chinese medicine 
(berberine48 and hispidulin49). Metformin, which is now prescribed to more than 100 million people 
with type 2 diabetes worldwide, was derived from the natural product galegine extracted from Galega 
officinalis, a plant reputedly used to treat diabetes-like conditions in medieval Europe. Although 
metformin activates AMPK, this may not explain all of the therapeutic effects of the drug. In fact, 
AMPK-α1 knockout mice that also carry a liver-specific deletion of AMPK-α2 display a normal 
hypoglycemic response to metformin, and the acute effects of metformin on glucose production in 
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isolated hepatocytes are also preserved4. The latter effect may be explained by metformin causing an 
increase in AMP that directly inhibits the gluconeogenic enzyme fructose-1,6-bisphosphatase. One 
caveat in the interpretation of these experiments is that the fall in ATP (and hence the increase in AMP) 
caused by metformin was larger in cells lacking AMPK than in wild type cells4, suggesting that the 
inhibition of fructose-1,6-bisphosphatase by AMP may be accentuated in the absence of AMPK. Thus, 
although not completely ruling out a role for AMPK in metformin action, these results do indicate that 
other targets, such as fructose-1,6-bisphosphatase, are also important. 
 It has been suggested that metformin activates AMPK in L6 cells by inhibiting AMP deaminase (the 
enzyme that breaks down AMP) thus causing AMP to accumulate50. While this is an interesting 
proposal, the concentration of metformin used to inhibit AMP deaminase (10 mM) was very high. The 
same study also reported that the effect of metformin to activate AMPK was not reduced by siRNA 
knockdown of adenylate kinase. However, only the “cytosolic” AK1 isoform was knocked down, and 
not the mitochondrial isoform, AK2, which might be the more relevant isoform when studying effects 
of a mitochondrial inhibitor. Also, we now know that increased phosphorylation of AMPK can be 
triggered by an increase in ADP alone, obviating any requirement for adenylate kinase to generate 
AMP. 
 Intriguingly, some of the AMPK activators described above, including resveratrol and metformin, 
extend healthy lifespan in C. elegans, and genetic studies show that the AMPK ortholog is required for 
these effects, as well as for the life-extending effects of dietary restriction51, 52. In both C. elegans and 
mammalian cells, AMPK up-regulates genes involved in oxidative metabolism and oxidative stress 
resistance by regulating transcription factors of the DAF-16/FOXO family53, 54. This might contribute 
to its effects on healthy lifespan. 
 An important question is how these drugs and xenobiotics all manage to activate AMPK, despite the 
fact that their structures are so varied. Most modulate AMPK in intact cells but not in cell-free assays, 
suggesting that they activate AMPK indirectly. Using a cell line that expresses an AMP- and ADP-
insensitive AMPK mutant, it has been shown that many of them, including metformin and resveratrol, 
activate AMPK indirectly by increasing cellular AMP and ADP, usually by inhibiting mitochondrial 
ATP synthesis55. Many of these natural products appear to be defensive compounds produced by plants 
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to deter infection by pathogens, or grazing by insect or mammalian herbivores. Consistent with this, 
resveratrol is produced in grapes in response to fungal infection56, while Galega officinalis is classed as 
a noxious weed in the USA because it is poisonous to herbivores. Since the mitochondrial respiratory 
chain and ATP synthase contain several large multiprotein complexes, they might have many potential 
binding sites for hydrophobic xenobiotics that might inhibit their function. Production of mitochondrial 
poisons would be a useful general strategy for plants to deter pathogens or herbivores, with the side 
effect that plants would provide a rich source of AMPK activators. One could argue that, by inhibiting 
mitochondrial ATP synthesis, these xenobiotics are acting in animals as mimetics of dietary restriction 
and/or exercise, both of which can decrease cellular energy status and have favorable effects on healthy 
lifespan. 
Activation by oxidative stress and genotoxic treatments 
 There are increasing indications that some types of cellular stress activate AMPK by “non-
canonical” mechanisms that may not involve increases in AMP, ADP or Ca2+ levels. In cultured cells, 
AMPK is activated by reactive oxygen species (ROS) such as H2O2. At high ROS concentrations, 
AMPK activation may be secondary to the inhibition of mitochondrial ATP synthesis, with consequent 
rises in AMP and ADP levels55. However, it has been suggested that there is also a more direct 
mechanism involving oxidation or glutathionylation [G] of two conserved cysteine residues in the 
AMPK-α subunit57. It has also been suggested that H2O2 can activate AMPK via a third mechanism 
involving a cytoplasmic form of the PI-3 kinase-like kinase, Ataxia-Telangiectasia Mutated (ATM)58, 
the product of the gene mutated in human ataxia-telangiectasia [G]. Nuclear ATM is activated by 
double strand breaks in DNA and is part of a key DNA damage-sensing pathway. However, it has 
recently become clear that there is also a cytoplasmic pool of ATM that has a role in the response to 
oxidative stress59. AMPK activation by low concentrations of H2O2 is reduced in fibroblasts from 
ataxia-telangiectasia patients or mouse embryo fibroblasts lacking ATM. ATM-dependent activation of 
AMPK by oxidative stress seems to require LKB1, since it is attenuated in cells lacking this upstream 
kinase58. Interestingly, ATM can phosphorylate LKB1, although it is not clear that this has any effect 
on LKB1 activity60. 
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 Another class of factors that activate AMPK are genotoxic, DNA-damaging treatments such as 
etoposide61, doxorubicin62 and ionizing radiation63, which activate AMPK initially in the nucleus63. 
There is evidence that these effects also require ATM but, surprisingly, they do not require LKB1 
because the pathway is functional in LKB1-null cells61, 63. The detailed mechanism for this effect 
remains unclear. Finally, a recent genome-wide association study identified a strong association 
between single nucleotide polymorphisms that mapped to the Atm gene on chromosome 11 and 
enhanced hypoglycemic response to metformin treatment in humans64. Although the molecular 
explanation for this association remains unclear, it provides another tantalizing link between 
metformin, ATM and AMPK. 
 To summarize this section, AMPK is activated in intact cells both by “canonical” pathways 
involving increases in AMP, ADP or Ca2+, and by “non-canonical” pathways such as those triggered by 
ROS and DNA damaging agents. The latter may involve the PI-3-like kinase ATM, although the 
detailed mechanisms involved remain unclear. 
Regulation of cellular energy metabolism 
AMPK and its orthologs phosphorylate downstream targets at serine/threonine residues within a 
characteristic sequence motif, which has hydrophobic residues at the -5 and +4 positions and basic 
residues at -4 and -3, or both65, 66. Another basic residue at -6 is an additional positive determinant, 
while the best substrates (such as acetyl-CoA carboxylase-1/-α) have additional hydrophobic residues 
forming an amphipathic helix N-terminal to the -5 position67. The principal effects of AMPK activation 
on cell metabolism are summarized in Fig. 4. Consistent with a role in maintaining energy homeostasis, 
when AMPK is activated by energetic stress it switches on catabolic pathways that generate ATP, 
while switching off biosynthetic pathways that consume ATP. 
Regulation of glucose uptake by the glucose transporter GLUT4 
Catabolic events mediated by AMPK include enhanced glucose uptake during muscle contraction, 
when the major metabolic fate of the glucose is catabolism to generate ATP. Muscle glucose uptake is 
also promoted by the hormone insulin, although this mainly occurs in resting muscle when the major 
metabolic fate of the glucose is glycogen synthesis, an anabolic process. In both cases, enhanced 
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glucose uptake is mediated through translocation of the glucose transporter GLUT4 from intracellular 
storage vesicles to the plasma membrane. Fusion of these vesicles with the plasma membrane requires 
members of the Rab family of G proteins to be in their GTP-bound state68. Under basal conditions Rabs 
are held in an inactive GDP-bound state by Rab-GAPs such as AS160 (also known as TBC1D4) and 
TBC1D1, which are associated with the GLUT4 storage vesicles. The insulin-activated kinase Akt 
phosphorylates AS160 in muscle and adipocytes, triggering its association with 14-3-3 proteins and its 
consequent dissociation from the vesicles69-71. Similarly, AMPK phosphorylates TBC1D1 in 
contracting muscle, with similar effects72, 73. In either case, dissociation of these Rab-GAPs triggers the 
conversion of Rabs to their active, GTP forms and the consequent fusion of the vesicles, carrying their 
GLUT4 cargo, with the plasma membrane. Consistent with this model, mice with a knock-in mutation 
(T649A) at a key Akt phosphorylation site in AS160 show impaired glucose disposal in vivo and 
impaired insulin-stimulated glucose uptake with isolated muscle71. It would be very interesting to 
perform similar experiments with the AMPK site on TBC1D1, to confirm the mechanism by which 
AMPK regulates glucose uptake in contracting muscle. 
 Whether AMPK, working via phosphorylation of TBC1D1 and perhaps other targets, entirely 
accounts for the acute effects of contraction on muscle glucose transport has been a matter of some 
controversy. In mouse knockouts of AMPK-α2 (the major catalytic subunit isoform in muscle), the 
stimulatory effects of the AMPK activator 5-aminoimidazole-4-carboxamide riboside (AICAR) on 
glucose uptake were lost, but the effects of contraction were normal. In AMPK-α1 knockout mice, both 
responses were normal74. By contrast, in mice with muscles lacking the upstream kinase LKB1 (in 
which activation of both AMPK-α1 and AMPK-α2 complexes by contraction was abolished), the 
effects of both AICAR and contraction on glucose uptake were lost2. One explanation for these 
discrepancies is that AMPK-α1 may be able to compensate for AMPK-α2 when the latter is absent. 
Recent results with muscle-specific AMPK-β1-/- AMPK-β2-/- double knockout mice, which lack any 
detectable AMPK activity, have supported the idea that AMPK activation is crucial during muscle 
contraction. The running speed and endurance of these mice was dramatically reduced, and they 
exhibited blunted muscle glucose uptake in response to treadmill exercise, and markedly impaired 
contraction-stimulated glucose uptake in isolated muscles75. These results are consistent with the idea 
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that AMPK represents the primary signalling pathway responsible for contraction-induced glucose 
uptake, although TBC1D1 may not be the only downstream target that mediates this effect. 
Regulation of other catabolic pathways 
 AMPK also promotes glucose uptake into cells expressing only GLUT1 (which includes most cells 
other than those in muscle, liver and adipose tissue), via a mechanism that involves activation of 
GLUT1 that is already located at the plasma membrane76. Moreover, it promotes fatty acid uptake into 
cardiac myocytes via translocation of vesicles containing the fatty acid transporter CD36 to the plasma 
membrane77. The direct targets for AMPK that mediate these effects remain unknown. Once they have 
entered the cell, AMPK can promote the catabolism of glucose via glycolysis, and of fatty acids by 
enhancing their uptake into mitochondria and their consequent breakdown by the β-oxidation pathway. 
Activation of glycolysis occurs via phosphorylation of 6-phosphofructo-2-kinase (PFK2), which 
catalyzes the generation of fructose-2,6-bisphosphate, a key allosteric activator of the glycolytic 
enzyme 6-phosphofructo-1-kinase. However, this only occurs in cells expressing the PFKFB2 isoform 
of PFK2, such as cardiac myocytes39, or the PFKFB3 isoform, such as monocytes and macrophages78. 
Uptake of fatty acids into mitochondria, which appears to be the rate-limiting step in β-oxidation, is 
promoted by AMPK via phosphorylation and inactivation of the ACC2/ACCβ isoform of acetyl-CoA 
carboxylase. This results in a drop in concentration of the acetyl-CoA carboxylase product, malonyl-
CoA, an inhibitor of fatty acid entry into mitochondria mediated by the carnitine-palmitoyl-CoA 
transferase-1 (CPT1) system79. 
Regulation of mitochondrial biogenesis and mitophagy 	   Another critical process activated by AMPK is mitochondrial biogenesis (Fig. 4), which in the 
longer term generates increased capacity for the oxidative catabolism of both glucose and fatty acids. 
Repeated daily dosing of rats with AICAR results in increased expression of mitochondrial genes in 
muscle80 as well as increased exercise endurance81 (the latter finding prompted the World Anti-Doping 
Agency to ban the use of AICAR in competitive sports). The AMPK-β1-/- AMPK-β2-/- double 
knockout mice mentioned above, which lack any AMPK activity in muscle, also had greatly reduced 
muscle mitochondrial content75. The “master regulator” of mitochondrial biogenesis is PGC-1α, a co-
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activator that enhances the activity of several transcription factors acting on nuclear-encoded 
mitochondrial genes82. AMPK directly phosphorylates PGC-1α, which has been proposed to cause 
activation of its own transcription via a positive feedback loop83. An alternative mechanism by which 
AMPK has been proposed to activate PGC-1α is through promotion of its deacetylation, by increasing 
the concentration of NAD, the co-substrate for the deacetylase SIRT184. 
 As well as increasing mitochondrial biogenesis, AMPK is involved in the turnover of mitochondria 
via the special form of autophagy termed mitophagy (Fig. 4). ULK1 and ULK2, the mammalian 
orthologs of the yeast Atg1 kinase that initiates the autophagy cascade, form stable complexes with 
AMPK85, and AMPK phosphorylates and activates ULK1, thus triggering autophagy86, 87. In cells in 
which endogenous ULK1 was replaced by a kinase-inactive mutant, or by a mutant in which the 
AMPK phosphorylation sites were substituted by alanine, mitochondria with aberrant morphology and 
reduced membrane potential accumulated following nutrient starvation86. This supports the idea that 
phosphorylation of ULK1 by AMPK is required for the clearance of dysfunctional mitochondria. 
Mitochondria are the main site of production of reactive oxygen species in the cell, and are particularly 
susceptible to oxidative damage. By recycling components of damaged mitochondria, mitophagy may 
be as important in maintaining a healthy cellular ATP-generating capacity as is the production of new 
mitochondria. 
Regulation of anabolic pathways 
Consistent with its role in cellular energy homeostasis, AMPK also conserves ATP by switching off 
almost all anabolic pathways, including the biosynthesis of lipids, carbohydrates, proteins and 
ribosomal RNA. It achieves this in part by phosphorylating and/or regulating enzymes or regulatory 
proteins directly involved in these pathways, including acetyl-CoA carboxylase88 
(ACC1/ACCα isoform, involved in fatty acid synthesis), glycerol phosphate acyl-transferase89 
(triglyceride/phospholipid synthesis), HMG-CoA reductase90 (cholesterol synthesis), glycogen 
synthase91 (glycogen synthesis), TSC292 and RAPTOR66 (regulators of the target-of-rapamycin (TOR) 
kinase, which promotes protein synthesis) and TIF-IA/RRN393 (a transcription factor for RNA 
polymerase I, responsible for ribosomal RNA synthesis). In many cases, AMPK also down-regulates 
expression of the proteins involved in these pathways, including ACC1/ACCα and other lipogenic 
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enzymes (probably via phosphorylation of the lipogenic transcription factor SREBP-1C94) and the 
gluconeogenic enzymes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase (by 
phosphorylation of the transcriptional co-activator CRTC2, formerly known as TORC295, and/or by 
phosphorylation and nuclear exclusion of the Class IIa HDAC family, which deacetylate and activate 
FOXO family transcription factors96). With the exception of gluconeogenesis, most of these anabolic 
pathways are required for cell growth, and in many cases expression of the enzymes involved is up-
regulated in tumors. By down-regulating these pathways, AMPK not only conserves ATP, but also 
exerts a cytostatic, anti-tumor effect, consistent with the hypothesis that it exerts most, if not all, of the 
tumor suppressor effects of its upstream kinase, LKB1. 
Regulation of whole body energy metabolism 
In mammals, AMPK can also influence metabolism and energy balance at the whole body level, 
particularly through its actions in the hypothalamus of the brain. 
AMPK and control of appetite 
The primary appetite control centre is the arcuate nucleus [G] of the hypothalamus, in which increased 
electrical activity in neuropeptide Y and agouti-related protein-expressing neurons (NPY/AgRP 
neurons) [G] induces feeding, while increased activity in neurons expressing pro-opiomelanocortin 
(POMC neurons) [G] inhibits feeding97. Kinase assays in dissected hypothalamic regions from rodents 
show that hormones that inhibit feeding, such as the adipokine leptin, inhibit the α2 isoform of 
AMPK98, whereas those that promote it, such as the hormone ghrelin [G] from the stomach, the 
adipokine adiponectin, or cannabinoids, activate AMPK (the specific isoform was not determined)98-101. 
Direct injection into the hypothalamus of pharmacological activators of AMPK, or DNAs encoding 
activated mutants, also promotes feeding98, 99. 
 Although leptin inhibits AMPK-α2 in the hypothalamus98, mice in which AMPK-α2 was 
specifically knocked out in NPY/AgRP neurons or POMC neurons displayed only minor changes in 
food intake, and still exhibited decreased food intake in response to leptin102. A possible explanation 
for this anomaly was provided by a recent report suggesting that it is in presynaptic neurons [G] 
upstream of NPY/AgRP neurons, rather than in the NPY/AgRP or POMC neurons themselves, that 
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regulation of AMPK is critical103. The frequency of miniature excitatory postsynaptic currents [G] in 
the NPY/AgRP neurons was used as a measure of neurotransmitter release from presynaptic neurons 
acting upstream. Using various pharmacological agents, evidence was obtained for a model in which 
ghrelin, which is released from the stomach during fasting, activates AMPK in presynaptic neurons via 
GHSR1 receptors (Fig. 5a). These receptors activate heterotrimeric G proteins containing Gq/G11, which 
trigger intracellular Ca2+ release and therefore lead to the activation of AMPK by the CaMKKβ 
pathway104. Consistent with this, CaMKKβ-deficient mice show reduced expression of NPY and 
AgRP, but not POMC, in the hypothalamus, and fail to increase their food intake in response to 
ghrelin105. Although the critical downstream target(s) for AMPK in the presynaptic neurons remain 
unclear, its activation appears to initiate a positive feedback loop in which Ca2+ release via ryanodine 
receptors [G] causes sustained activation of AMPK and release of Ca2+, and consequent 
neurotransmitter release onto the NPY/AgRP neurons. This in turn promotes sustained feeding, which 
due to the positive feedback loop continues even after ghrelin stimulation has ceased. According to this 
model, feeding only stops when leptin released by adipocytes stimulates release from neighbouring 
POMC neurons of opioids, which act via µ-opioid receptors in the presynaptic neurons upstream of the 
NPY/AgRP neurons to inhibit AMPK (the mechanism for this latter effect remains unknown) (Fig. 5b). 
An interesting parallel exists between this proposed neural circuit and the “reset-set” or “flip-flop” 
memory storage circuits used in electronic devices. These circuits are switched on by signals coming in 
via the “set” input, and remain switched on even in the absence of further stimulation until a signal is 
received on the “reset” input. By analogy, hunger signals such as ghrelin represent the “set” inputs that 
switch on AgRP neurons and trigger feeding, and feeding would continue until the satiety signal, leptin, 
resets the circuit by acting on the POMC neuron. This model is consistent with observed diurnal 
patterns of plasma ghrelin and leptin in humans eating normal meals106. If excess food is available, it 
may have survival value to continue eating until the leptin signal coming from adipocytes indicates that 
fat stores have been replenished, rather than stopping eating as soon as the hunger signal from the 
stomach (ghrelin) had ceased. 
Role of AMPK in glucose sensing and modulation of the sympathetic nervous system 
 AMPK in the neighboring ventromedial hypothalamus also appears to have important roles in 
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controlling whole body energy balance. There is evidence that it is involved in sensing of low blood 
glucose, promoting release of counter-regulatory hormones (epinephrine and glucagon) that stimulate 
glucose production by the liver107. Thyroid hormones also inhibit AMPK in this region108, increasing 
the activity of sympathetic nerves, which increase energy expenditure by promoting fat oxidation in 
muscle or brown adipose tissue108. Interestingly, in whole body mouse knock-outs of AMPK-α2 there 
is elevated production of catecholamines109, consistent with the idea that inhibition of AMPK can 
promote activity of the sympathetic nervous system. 
AMPK and circadian rhythms 
 In most mammals, whole body metabolism exhibits circadian rhythms, via which the timing of 
feeding and metabolism are synchronized with the daily cycle of light and darkness. The 
suprachiasmatic nucleus [G] of the hypothalamus is the site of the “master clock” that generates these 
rhythms. However, the proteins involved in establishing these rhythms are also expressed at peripheral 
sites such as the liver, forming “slave clocks” that can oscillate independently under certain 
circumstances110. These proteins include the transcription factors Bmal1 and Clock, which form a 
heterodimer that activates the expression of many genes, two of which are the Per (period) and Cry 
(cryptochrome) genes. Once synthesized, Per and Cry proteins bind to each other, become 
phosphorylated and then enter the nucleus, where they inhibit the Clock:Bmal1 complex. This delayed 
negative feedback loop results in the rhythmic expression not only of Per and Cry themselves, but also 
of numerous other genes driven by Bmal1/Clock. AMPK has been found to phosphorylate Cry1, 
reducing its association with Per2 and instead increasing its binding to FBXL3, a ubiquitin ligase that 
promotes Cry1 ubiquitylation and degradation111. This would have the effect of extending the period of 
the endogenous rhythm. In mouse embryo fibroblasts synchronized by serum starvation, treatment with 
low glucose or the AMPK activator AICAR reduced the amplitude, and increased the period, of the 
circadian rhythm of a luciferase reporter gene driven by the Bmal1/Clock promoter; these effects were 
lost in cells lacking LKB1 or AMPK. It has been known for many years that the phosphorylation of 
AMPK targets such as acetyl-CoA carboxylase follows a circadian rhythm in rodent liver linked to the 
times of feeding88. The more recent results111 suggest that AMPK may have a crucial role in 
determining these circadian rhythms. 
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AMPK functions beyond metabolism 
Although AMPK is best known for its effects on metabolism, it has recently become clear that is 
mediates other effects not directly related to metabolism. Two of these are regulation of the cell cycle 
and modulation of membrane excitability. 
Regulation of the cell cycle 
Both DNA replication (in S phase) and mitosis (in M phase) are energy-requiring processes, and it 
would make little sense for cells that are deficient in energy to execute them. Consistent with this, 
activation of AMPK in cycling cells causes a G1 arrest prior to S phase112. This is associated with 
phosphorylation of p53 at Ser-15 (although it is not clear that this is a direct target for AMPK) and up-
regulation of expression of the G1 cyclin-dependent kinase inhibitor p21WAF1, a product of a p53-
activated gene112, 113. AMPK has also been reported to phosphorylate the C-terminal residue of another 
cyclin-dependent kinase inhibitor, p27KIP1, causing its stabilization114. These effects may explain, at 
least in part, the ability of AMPK to cause cell cycle arrest. 
 Surprisingly, other studies suggest that AMPK activity is required for completion of mitosis. An 
elegant chemical genetic screen, involving expression of AMPK-α2 with a mutation in the catalytic site 
that allowed it to utilize a chemically modified ATP, identified several novel targets for AMPK, all of 
which conformed with the established AMPK recognition motif65, 66. Many of these novel targets had 
roles in mitosis and cytokinesis, including components of the anaphase promoting complex (APC1 and 
CDC27), three of the regulatory subunits (PPP1R12A/B/C) that target protein phosphatase-1 to 
dephosphorylate myosin regulatory light chain (MRLC) at Ser19, and the protein kinase PAK2, which 
phosphorylates MRLC at Ser19115. The phosphorylation of both AMPK (Thr172) and PPP1R12C at the 
AMPK site (Ser452) were elevated in mitotic cells, and stable expression of a S452A mutant 
PPP1R12C led to an increase in the proportion of multinucleated cells, indicating a defect in mitosis or 
cytokinesis. Relevant to this are findings that AMPK phosphorylated at Thr172 is specifically localized 
at several places within the mitotic apparatus in mitotic cells116. Intriguingly, Drosophila embryos 
carrying AMPK-null mutations also display a high frequency of multinucleate or polyploid cells, and 
this could be rescued by expressing MRLC with phosphomimetic mutations at the sites equivalent to 
Thr18 and Ser19 in human MRLC117. 
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 It is not immediately apparent why a kinase activated by energy stress should be required for 
passage through mitosis. Perhaps mitosis is accelerated by AMPK in cells undergoing stress in order 
that an orderly cell cycle arrest may occur in the ensuing G1 phase. However, it may be that this is an 
ancillary function of AMPK unrelated to its role as an energy sensor. 
Regulation of membrane excitability 
Remarkably, ATP turnover in the grey matter of brain is comparable with that in leg muscle during 
marathon running, explaining why an organ contributing only 2% of body weight can account for 
>20% of resting metabolism118. It has been estimated that the firing of action potentials accounts for 
25–50% of this energy consumption, with synaptic transmission (which is triggered by action 
potentials) contributing most of the remainder118, 119. A mechanism that down-regulated the firing of 
neuronal action potentials would therefore conserve a considerable amount of energy. Recent studies 
with HEK-293 cells stably expressing the potassium channel Kv2.1 showed that AMPK activation was 
found to activate these potassium channels by causing a shift in voltage gating to more negative 
membrane potentials. Identical effects were observed when activated AMPK (thiophosphorylated at 
Thr172 to make it resistant to phosphatases), but not an inactive mutant, was introduced into the cells 
via the patch pipette120. AMPK phosphorylates purified Kv2.1 at two sites in its cytoplasmic C-terminal 
tail, and the effect of AMPK activation on voltage gating was lost in cells in which one of these 
(Ser440) was substituted with a non-phosphorylatable alanine120. Kv2.1 accounts for a large proportion 
of the delayed rectifier K+ channels [G] in central neurons, and their activation has been proposed to 
reduce the firing of action potentials down the axon121. Interestingly, introduction of active 
thiophosphorylated AMPK, but not an inactive mutant, into cultured rat hippocampal neurons via the 
patch pipette caused a progressive decrease in the frequency of action potentials induced by a current 
pulse120. These results support the idea that AMPK activation may exert a neuroprotective role by 
limiting the rate of firing of action potentials, thus conserving energy when the energy status of 
neuronal tissue is compromised.	  
Conclusions and outstanding questions 
 There are now around one thousand papers on AMPK and its orthologs published every year, and in 
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this review we have only been able to cover a small number that we found particularly interesting. The 
classical pathways by which AMPK is activated by increases in AMP:ATP or ADP:ATP ratios, or 
increases in Ca2+, are now becoming well understood, although our understanding of the protein 
phosphatases that dephosphorylate Thr-172 remains incomplete. The “non-canonical” mechanisms by 
which oxidative stress and genotoxic agents activate AMPK are another area that needs further 
investigation. Although AMPK is perhaps best known for its effects to regulate metabolism at the 
cellular level, in mammals it also regulates metabolism and helps to maintain energy balance at the 
whole body level. It does this by mediating effects of hormones and other agents acting on neurons in 
different hypothalamic regions, which regulate intake of food (and hence energy) and energy 
expenditure. AMPK also regulates diurnal rhythms of feeding and metabolism. By switching off 
biosynthetic pathways required for cell growth, AMPK activation would exert a cytostatic effect, 
helping to explain why its upstream activator, LKB1, is a tumor suppressor. Commensurate with its 
role in preserving cellular energy homeostasis, AMPK also down-regulates ATP-requiring processes 
outside of metabolism, including progress through the cell cycle (another potential tumor suppressor 
effect) and firing of action potentials in neurons. Although it might be said that the AMPK field is 
approaching maturity, it seems certain that many exciting findings about the pathway remain to be 
discovered, and these insights might lead to novel drugs and other means of exploiting this knowledge. 
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Figure Legends 
Figure 1: Model for the mechanism by which AMPK is activated by increases in AMP and ADP 
(top), as the cellular concentrations of ATP, ADP and AMP change (bottom).  The model at 
the top represents different states of the three subunits of AMPK (see Fig. 2 for details of 
domains). The graph at the bottom shows changes in the predicted concentrations of ATP, 
ADP and AMP on going from an unstressed, fully charged cell (left) to a cell undergoing a 
severe energy stress (right), corresponding to a 10-fold increase in ADP:ATP ratio. The 
graph was generated by assuming that the adenylate kinase reaction was at equilibrium. 
Note that in a fully charged cell (left), AMP concentration is very low, but that its % 
change in concentration as ADP/ATP increases is always much greater than those of ATP 
or ADP. In the model at the top, the basal state (top left) has sites 1 and 3 in the γ subunit 
occupied by ATP (site 4 is always occupied by AMP). Replacement of ATP by ADP (or 
AMP) at site 3 during moderate stress  (top centre) promotes phosphorylation of Thr172 
(bottom centre), causing a 100-fold increase in activity (indicated by two stars). 
Replacement of ATP by AMP at site 1 during more severe stress causes a further 10-fold 
allosteric activation (indicated by a third star, bottom right). As cellular energy status 
returns to normal, AMP at site 1 and ADP or AMP at site 3 are progressively replaced by 
ATP (moving from right to left on the bottom row).  This promotes the dephosphorylation 
of Thr-172 and a return to the basal state. 
Figure 2: Domain map of typical mammalian AMPK. Colour coding of domains are similar to those 
in Figs. 1 and 3. AMPK complexes are heterotrimers composed of α, β and γ subunits in a 
1:1:1 ratio. Key to acronyms: N-lobe, N-terminal lobe of kinase domain; C-lobe, C-
terminal lobe of kinase domain; AID, auto-inhibitory domain; α-CTD, α subunit C-
terminal domain; CBM, carbohydrate-binding module; β-CTD, β subunit C-terminal 
domain; CBS1-4, CBS repeats in γ subunit. The β-CTD forms the core of the complex, 
binding to the α-CTD and the N-terminus of the γ subunit prior to CBS1. 
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Figure 3: Two views of a crystal structure of a partial heterotrimeric complex of mammalian 
AMPK16; the right-hand view is rotated about 180o about the y axis compared to the left-
hand view. The constructs crystallized contained only the C-terminal domain of the β 
subunit and also lacked a flexible loop in the C-terminal domain of the α subunit. The α 
subunit AID was present but was not resolved in this crystal form; in the left-hand view, its 
approximate location would just to the right of the junction between the α subunit C-lobe 
(green) and the α-linker (red). The crystals contained AMP bound at sites 3 and 4. Note 
how in this structure, access to the Thr172 site is restricted by the close association of the 
α-CTD with the kinase domain (left-hand view). In addition, note how AMP bound in site 
3 is not visible because it is covered by the “α-hook” structure of the linker peptide (right-
hand view, linker peptide in red). Key to acronyms: N-lobe, N-terminal lobe of kinase 
domain; C-lobe, C-terminal lobe of kinase domain; γ-NTD, N-terminal region of γ subunit; 
α-CTD, α subunit C-terminal domain; β-CTD, β subunit C-terminal domain; γ-CBS1-4, 
CBS repeats in γ subunit. 
Figure 4: Summary of effects of AMPK activation on cellular metabolism. The likely protein targets 
that mediate the metabolic effects of AMPK, as well as the final metabolic outcomes, are 
depicted. Proteins shown on the inner wheel with question marks may not be directly 
phosphorylated by AMPK. Catabolic pathways, including glucose uptake via GLUT4 and 
GLUT1, glycolysis, fatty acid uptake via CD36, fatty acid oxidation, mitochondrial 
biogenesis and autophagy are invariably activated by AMPK. Anabolic pathways, including 
fatty acid synthesis, transcription of lipogenic enzymes, triglyceride synthesis, cholesterol 
synthesis, transcription of gluconeogenic enzymes, glycogen synthesis, protein synthesis 
and rRNA synthesis, are invariably inhibited by AMPK. 
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Figure 5: AMPK-regulated control of feeding behavior by modulation of neuropeptide Y- and agouti-
related protein-expressing neurons (NPY/AgRP neurons) and pro-opiomelanocortin 
neurons (POMC neurons), as proposed by Yang et al103. A) in the fasted state ghrelin, a  
“hunger signal” derived from the stomach, activates AMPK in the presynaptic neurons 
acting upstream of NPY/AgRP neurons via the CaMKKβ pathway. This causes release of 
Ca2+ by Ca2+-induced release from intercellular stores via ryanodine receptors, creating a 
feedback loop that causes continued release of neurotransmitter onto the NPY/AgRP 
neuron, even when ghrelin stimulation ceases. The NPY/AgRP neurons promote feeding 
(and inhibits the POMC neurons, which inhibit feeding). b) Feeding continues (even in the 
absence of ghrelin) until the POMC neurons are stimulated by the “satiety signal”, leptin. 
Activity of these neurons inhibits feeding and also promotes release of opioids that inhibit 
AMPK in the presynaptic neurons upstream of the NPY/AgRP neurons, switching them 
back to an inactive state. 
 
Glossary 
activation loop a sequence segment in the C-terminal lobe of protein kinases that 
often plays a key role in switching the kinase on; in many cases 
the kinase is only active after phosphorylation of this loop 
allosteric activation the activation of an enzyme by non-covalent binding of a ligand 
(an allosteric activator) that binds at a site distinct from the 
catalytic site 
arcuate nucleus an anatomical region of the hypothalamus at the base of the brain 
that appears to have a particular role in feeding and appetite 
ataxia-telangiectasia an inherited human disorder of which the clinical signs include 
ataxia (uncoordinated movement) and telangiectasia (dilated 
blood vessels in the skin or mucous membranes); caused by 
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mutation of the ATM gene, encoding a protein kinase of the 
phosphatidylinositol-3- kinase-like kinase (PIKK) family 
Bateman domain a domain formed by two tandem CBS repeats that associate 
together with central clefts that bind small molecules, especially 
adenosine derivatives 
CBS repeat sequence motif usually occurring as two tandem repeats that 
form a Bateman domain; named after cystathionine β-synthase, 
in which the Bateman domain binds S-adenosyl methionine 
circadian rhythm a biological rhythm that follows the normal 24 hour cycle; 
although endogenously driven and thus continuing in the absence 
of external cues, they are often entrained or modified by external 
stimuli such as light or food availability 
delayed rectifier K+ channels a group of voltage-gated K+ channels that open and close slowly 
in response to membrane depolarization; by allowing K+ ions to 
flow out of cells down their concentration gradient and thus 
oppose subsequent depolarization, these channels regulate the 
frequency of action potentials 
fructose-1,6-bisphosphatase enzyme that catalyzes a key regulatory step in gluconeogenesis 
(hydrolysis of fructose-1,6-bisphosphate to fructose-6-
phosphate) in the liver and kidney 
ghrelin a 28 amino acid peptide that is released by cells of the stomach 
and represents a “hunger signal” 
glutathionylation the covalent attachment of glutathione to a protein, via the 
formation of a mixed disulfide between the cysteine moiety of 
glutathione and a cysteine side chain of the protein 
glycogen phosphorylase the primary enzyme that mobilizes stores of glucose in glycogen, 
catalyzing the release of glucose-1-phosphate from the non-
reducing ends of glycogen by a phosphorylysis reaction 
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LKB1:STRAD:MO25 complex a heterotrimeric complex containing the tumor suppressor 
protein kinase, LKB1, and the accessory subunits STRAD and 
MO25; LKB1 was discovered as the gene mutated in a form of 
inherited cancer susceptibility (Peutz-Jeghers syndrome), and is 
also lost due to somatic mutation in many human cancers 
membrane excitability some biological membranes, such as the plasma membranes of 
neurons, are excitable because they contain voltage-gated Na+ 
channels that open in response to depolarization, allowing Na+ 
ions to flood into the cell down their concentration gradient; this 
amplifies the depolarization and causes a wave of depolarization 
(an action potential) to travel along the membrane 
miniature excitatory postsynaptic small depolarizing currents measured by patch clamping of a  
currents neuron, due to release of packets of neurotransmitter from a 
presynaptic neuron upstream of that neuron; they can be 
observed by applying tetrodotoxin to inhibit the firing of action 
potentials in the neuron 
mitophagy the special form of autophagy by which mitochondria (probably 
in a damaged or defective state) are engulfed by autophagosomes 
and degraded, recycling their contents for re-use 
NPY/AgRP neuron a neuron that expresses the neuropeptides neuropeptide Y and  
agouti-related protein 
N-terminal myristylation the covalent attachment of 14 carbon saturated fatty acid 
(myristic acid), usually to the N-terminus of a protein following 
cleavage of the initiating methionine 
phosphofructokinase enzyme that catalyzes a key regulatory step in glycolysis, the 
transfer of phosphate from ATP to fructose-6-phosphate to 
generate fructose-1,6-bisphosphate 
POMC neuron a neuron that expresses the neuropeptide pro-opiomelanocortin  
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presynaptic neuron a neuron acting immediately upstream of the neuron under study, 
which releases neurotransmitters directly onto that neuron 
Rab-GAP protein carrying a Rab-GTPase activator protein function, i.e. 
the ability to promote conversion of small G proteins of the Rab 
family from their active Rab-GTP state to their inactive Rab-
GDP state 
ryanodine receptors Ca2+ release channels in the sarcoplasmic/endoplasmic reticulum 
of muscle cells and neurons, which are activated by Ca2+ and 
blocked by the plant product, ryanodine 
ventromedial nucleus an anatomical region of the hypothalamus at the base of the brain 
that appears to have a role in glucose sensing and activation of 
the sympathetic nervous system 	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